Sarepta Therapeutics Inc (SRPT)

05:17 AM

Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com

05:17 AM

04:50 AM

Leerink Partners maintains Market Perform rating on Sarepta stock ahead of 2026 data - Investing.com UK

04:50 AM

12:10 PM

Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington’s Disease Trial Application - Yahoo Finance

12:10 PM

Jan 07, 2026

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigat - pharmiweb.com

Jan 07, 2026

Jan 07, 2026

Sarepta submits clinical trial application for Huntington’s disease drug By Investing.com - Investing.com India

Jan 07, 2026

Jan 07, 2026

Sarepta submits clinical trial application for Huntington’s disease drug - Investing.com

Jan 07, 2026

Jan 07, 2026

Sarepta (SRPT) Moves Forward with New Clinical Trial Application for Huntington's Treatment - GuruFocus

Jan 07, 2026

Jan 07, 2026

Sarepta submits clinical trial application for Huntington's disease drug - StreetInsider

Jan 07, 2026

Jan 07, 2026

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease - Yahoo Finance

Jan 07, 2026

Jan 06, 2026

Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stock2026 world cup usa national team round of 32 star players high defensive line expert forecast preview - Улправда

Jan 06, 2026

Jan 05, 2026

Standing by Our Decision: How EXONDYS 51 Became Part of Our Treatment Plan - Muscular Dystrophy News

Jan 05, 2026

Jan 05, 2026

Buybacks Report: What risks investors should watch in Sarepta Therapeutics Inc stockBreakout Watch & Intraday High Probability Setup Alerts - moha.gov.vn

Jan 05, 2026

Jan 05, 2026

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - New Castle News

Jan 05, 2026

Jan 05, 2026

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Biotech Pioneer with a Mixed Valuation Outlook - DirectorsTalk Interviews

Jan 05, 2026

Jan 05, 2026

Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC - MarketBeat

Jan 05, 2026

Jan 03, 2026

United States Neuromuscular Disease Therapeutics Market - openPR.com

Jan 03, 2026

Jan 01, 2026

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace

Jan 01, 2026

Dec 31, 2025

Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Dec 31, 2025

Dec 31, 2025

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets

Dec 31, 2025

Dec 31, 2025

More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals

Dec 31, 2025

Dec 30, 2025

Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Dec 30, 2025

Dec 30, 2025

Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com

Dec 30, 2025

Dec 30, 2025

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny - MSN

Dec 30, 2025

Dec 29, 2025

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 - openPR.com

Dec 29, 2025

Dec 28, 2025

Japan Gene Therapy Market is expected to reach US$ 904.94 Million - openPR.com

Dec 28, 2025

Dec 28, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Dec 28, 2025

Dec 26, 2025

Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - MSN

Dec 26, 2025

Dec 26, 2025

Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com

Dec 26, 2025

Dec 26, 2025

Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Dec 26, 2025

Dec 25, 2025

Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours - MSN

Dec 25, 2025

Dec 25, 2025

Sarepta Therapeutics Earnings Notes - Trefis

Dec 25, 2025

Dec 24, 2025

Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga

Dec 24, 2025

Dec 23, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5%Here's What Happened - MarketBeat

Dec 23, 2025

Dec 22, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - ACCESS Newswire

Dec 22, 2025

Dec 22, 2025

Sarepta to refinance $291M of existing notes due 2027 - MSN

Dec 22, 2025

Dec 22, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire

Dec 22, 2025

Dec 21, 2025

Aug Intraday: Will Sarepta Therapeutics Inc stock split attract more investorsOil Prices & Verified Momentum Stock Watchlist - moha.gov.vn

Dec 21, 2025

Dec 20, 2025

Have Insiders Sold Sarepta Therapeutics Shares Recently? - simplywall.st

Dec 20, 2025

Dec 20, 2025

How Sarepta Therapeutics Inc. stock compares to industry benchmarksPortfolio Gains Report & Real-Time Market Trend Scan - ulpravda.ru

Dec 20, 2025

Dec 19, 2025

Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities By Investing.com - Investing.com Nigeria

Dec 19, 2025

Dec 19, 2025

Sarepta Therapeutics Extends Debt Maturities with New Notes - TipRanks

Dec 19, 2025

Dec 19, 2025

Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities - Investing.com

Dec 19, 2025

Dec 19, 2025

Sarepta Therapeutics Signs Multiple Financing Agreements - TradingView — Track All Markets

Dec 19, 2025

Dec 19, 2025

What Does the Market Think About Sarepta Therapeutics Inc? - Benzinga

Dec 19, 2025

Dec 19, 2025

Is Sarepta Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Patterns & Reliable Price Action Trade Plans - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan Sells 13,187 Shares - MarketBeat

Dec 18, 2025

Dec 18, 2025

Insider Sale: Chief Operating Officer of $SRPT Sells 13,187 Shares - Quiver Quantitative

Dec 18, 2025

Dec 18, 2025

Sarepta Therapeutics COO Sells Shares - TradingView — Track All Markets

Dec 18, 2025

Dec 18, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - ACCESS Newswire

Dec 18, 2025

Dec 18, 2025

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Finviz

Dec 18, 2025

Dec 18, 2025

Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Yahoo Finance

Dec 18, 2025

Dec 18, 2025

Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' (SRPT) Risk‑Reward Narrative? - Sahm

Dec 18, 2025

Dec 18, 2025

Will Sarepta Therapeutics Inc. stock maintain momentum in 2025Exit Point & Technical Buy Zone Confirmations - Улправда

Dec 18, 2025

Dec 17, 2025

Sarepta Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Low Entry Investment Portfolio - earlytimes.in

Dec 17, 2025

Dec 17, 2025

Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - Stock Traders Daily

Dec 17, 2025

Dec 17, 2025

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Dec 17, 2025

Dec 17, 2025

Sarepta Therapeutics Applauds Addition of Duchenne Muscular Dystrophy to the U.S. Recommended Uniform Screening Panel (RUSP) - Sarepta Therapeutics

Dec 17, 2025